AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application. Support for the amended and new claims can be found in the specification, as identified in the table attached hereto. Please cancel claims 4, 7-19, and 23, amend claims 1, 3, 5-6, 20, 22, and 24-25, and also add new claims 26 to 45 as follows:

1. (Currently amended) A system for quantitative measurement of percent glycated hemoglobin in whole blood, comprising:

a blood dilution solution; and

a device adapted for:

receiving at least a portion of diluted blood solution[[.]];

~~for~~ contacting the blood solution with a dry immunoassay reagent system for detecting a change in the reagent system; and

~~for~~ providing an indication of the analytical result to the user;

wherein the blood dilution solution comprises a first surfactant for hemolysis and a second surfactant for stability.

2. (Original) A system according to claim 1 wherein the first surfactant is a zwitterionic surfactant.

3. (Currently amended) A system according to claim 1 wherein the first surfactant is a nonionic surfactant and the second surfactant is a ~~nonionic~~ zwitterionic or an ionic surfactant.

4. (Canceled).

5. (Currently amended) A system according to claim [[4]]26, wherein the dry reagent system comprises a microparticulate label.

6. (Currently amended) A system according to claim 5 wherein the ~~dry reagent system comprises~~ microparticulate is a latex particle[[s]].

7. through 19. (Canceled).

20. (Currently amended) A system for detection of an analyte in a liquid sample comprising:

a sample dilution solution; and

a device adapted for:

receiving at least a portion of diluted sample solution[[,]];

~~for~~ contacting the sample solution with a dry non-enzymatic binding assay reagent system adapted for indicating a change in the reagent system; and

~~for~~ providing an indication of the analytical result to the user;

wherein the sample dilution solution comprises a first surfactant for modification of the analyte and a second surfactant for stability.

21. (Original) A system according to claim 20 wherein the first surfactant is a zwitterionic surfactant.

22. (Currently amended) A system according to claim 20 wherein the first surfactant is a nonionic surfactant and the second surfactant is a ~~nonionic~~ zwitterionic surfactant.

23. (Canceled)

24. (Currently amended) A system according to claim [[23]]36, wherein the dry reagent system comprises a microparticulate label.

25. (Currently amended) A system according to claim 24 wherein the ~~dry reagent system comprises~~ microparticulate is a latex particle[[s]].

26. (New) A system according to claim 1 wherein the first surfactant is an ionic surfactant and the second surfactant is a zwitterionic or a nonionic surfactant.

27. (New) A system according to claim 2, 3 or 26, wherein the zwitterionic surfactant is

N-hexadecyl-N,N-dimethyl-3-amino-1-propanesulfonate and the nonionic surfactant is an ethoxylated acetylenic glycol polymer or a block copolymer of ethylene oxide and propylene oxide.

28. (New) A system according to claim 27, wherein the ethoxylated acetylenic glycol is ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol.

29. (New) A system according to claim 28, wherein the ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol has an ethylene oxide content of from about 40 to about 85% by weight.

30. (New) A system according to claim 29, wherein the ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol has an ethylene oxide content of about 85% by weight.

31. (New) A system according to claim 27, wherein the block copolymer of ethylene oxide and propylene oxide is a polyethylene oxide-polypropylene oxide- polyethylene oxide triblock copolymer or a polypropylene oxide-polyethylene oxide- polypropylene oxide triblock copolymer.

32. (New) A system according to claim 1, wherein the amount of the second surfactant in the blood dilution solution is from about 0.001% to 15% w/v.

33. (New) A system according to claim 1, wherein the amount of the second surfactant in the blood dilution solution is from about 0.01% to 10% w/v.

34. (New) A system according to claim 1, wherein the amount of the second surfactant in the blood dilution solution is from about 0.05% to 8% w/v.

35. (New) A system according to claim 1, wherein the amount of the second surfactant in the blood dilution solution is from about 0.1% to 5% w/v.

36. (New) A system according to claim 20 wherein the first surfactant is an ionic surfactant and the second surfactant is a zwitterionic or a nonionic surfactant.

37. (New) A system according to claim 21, 22 or 36, wherein the zwitterionic surfactant is N-hexadecyl-N,N-dimethyl-3-amino-1-propanesulfonate and the nonionic surfactant is an ethoxylated acetylenic glycol polymer or a block copolymer of ethylene oxide and propylene oxide.

38. (New) A system according to claim 37, wherein the ethoxylated acetylenic glycol is ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol.

39. (New) A system according to claim 38, wherein the ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol has an ethylene oxide content of from about 40 to about 85% by weight.

40. (New) A system according to claim 39, wherein the ethoxylated-2,4,7,9-tetramethyl-5-decyne-4,7-diol has an ethylene oxide content of about 85% by weight.

41. (New) A system according to claim 37, wherein the block copolymer of ethylene oxide and propylene oxide is a polyethylene oxide-polypropylene oxide- polyethylene oxide triblock copolymer or a polypropylene oxide-polyethylene oxide- polypropylene oxide triblock copolymer.

42. (New) A system according to claim 20, wherein the amount of the second surfactant in the sample dilution solution is from about 0.001% to 15% w/v.

43. (New) A system according to claim 20, wherein the amount of the second surfactant in the sample dilution solution is from about 0.01% to 10% w/v.

44. (New) A system according to claim 20, wherein the amount of the second surfactant in the sample dilution solution is from about 0.05% to 8% w/v.

45. (New) A system according to claim 20, wherein the amount of the second surfactant in the sample dilution solution is from about 0.1% to 5% w/v.